Your kidneys filter your blood through thousands of tiny units called glomeruli. In focal segmental glomerulosclerosis (FSGS), those filters scar.1
Scarred filters don’t heal. For 30% to 60% of patients, the median time to kidney failure is five to ten years.7
The toll in the U.S. today, according to Travere’s analysis of published and government data:7
- About 33,000 adults and children are living with kidney failure caused by FSGS.
- More than 4,000 people are on the kidney transplant waitlist because of it.
- Up to 55% of transplant patients see the disease come back in the new kidney.
Kidney failure means dialysis or a transplant. Medicare alone spent about $91,000 per patient per year on hemodialysis, in the most recent government cost report we could cite (2016 data).8
And until this year, according to Travere, doctors had no medicine approved for the disease itself.2
On April 13, 2026, the FDA approved FILSPARI (sparsentan) to reduce proteinuria (protein leaking into the urine) in adults and children aged 8 and older with FSGS without nephrotic syndrome. Its maker calls it “the first and only medicine approved by the FDA for the treatment of FSGS.”2 FILSPARI carries a boxed warning for liver toxicity and harm to an unborn baby, and is available only through a restricted program.4
That maker is Travere Therapeutics, Inc. (Nasdaq: TVTX).
How Big Is This?
Big, by the company’s own numbers.
FILSPARI is approved for two rare kidney diseases: FSGS since April, and IgA nephropathy before it.4 Travere estimates:7
- More than 30,000 addressable U.S. patients with FSGS.
- More than 70,000 addressable U.S. patients with IgA nephropathy.
- More than 100,000 U.S. patients in all.
- More than $3 billion in potential peak U.S. sales for FILSPARI.
For scale: the industry calls a drug that sells $1 billion a year a blockbuster.
In the second quarter of 2026, which included the April 13 FSGS approval:3
- FILSPARI U.S. net sales were $141.1 million, up 96% from a year earlier. That is a pace of roughly $560 million a year.
- Travere received 2,012 new patient start forms in the quarter.
- Total U.S. net product sales were $161.4 million, up from $94.8 million.
That pace is a little under one-fifth of Travere’s $3 billion peak estimate.

Beyond One Drug
Travere is also building a pipeline:3
- Pegtibatinase, for classical homocystinuria (HCU), a rare inherited metabolic disorder, is in a Phase 3 study, HARMONY. Topline data is expected in the second half of 2027.6
- Civorebrutinib, an oral drug licensed from Everest Medicines in July 2026 for $112.5 million upfront, which Travere plans to study in three more kidney diseases, including immune-mediated FSGS.
- Japan: partner Chugai filed for approval of sparsentan in Japan in June 2026. Travere is eligible for milestones and royalties.
- Patent: a U.S. patent covering certain uses of FILSPARI in IgA nephropathy has been allowed. Travere expects coverage into October 2037 once it issues.

The Balance Sheet
At June 30, 2026, Travere held $489.2 million in cash, cash equivalents and marketable securities.3 It is not yet profitable: its second-quarter GAAP net loss was $34.8 million.3 It also carries convertible debt with a carrying value of $602.8 million.5

The Bottom Line
FSGS puts tens of thousands of Americans on a path toward dialysis or a transplant. For the first time, an FDA-approved medicine is indicated for it: FILSPARI, approved to reduce proteinuria in adults and children 8 and older with FSGS without nephrotic syndrome.
Travere makes that medicine, sells it into a second kidney disease too, and says the combined U.S. opportunity exceeds $3 billion a year. FILSPARI’s U.S. sales were up 96% from a year earlier in the quarter it won the FSGS approval.
The open questions are how far and how fast that growth continues, given the drug’s safety monitoring, insurers’ decisions and competition, and whether the pipeline delivers.
Key risks
- Boxed warning and restricted access. FILSPARI carries a boxed warning for liver toxicity and harm to an unborn baby. It is available only through a restricted program (REMS) that requires liver tests before treatment and every 3 months during it.4
- Dependence on one product. Travere's results depend heavily on FILSPARI's commercial success, its acceptance by doctors and its coverage by insurers.5
- Continuing losses and dilution. The company reported a $34.8 million net loss in Q2 2026, says it may need substantial funding, and has convertible notes that can convert into shares. Travere also has an at-the-market program on file under which it may sell up to $100 million of new shares into the market (none sold as of June 30, 2026).3, 5
- Competition. Travere says it faces substantial generic and other competition, and it relies on third parties to make and distribute its products.5
- Clinical risk. The HARMONY Phase 3 study and the civorebrutinib program may not succeed.3, 6
- Leadership change. CEO Eric Dube steps down on December 1, 2026, and Bradley Campbell succeeds him.9
Forward-looking statements. Travere's patient estimates and its estimate of more than $3 billion in potential peak U.S. sales (May 2026), its expected HARMONY data timing (2H 2027), its planned civorebrutinib studies and its expected patent term (into October 2037) are company statements about future events. The "roughly $560 million a year" figure is Q2 2026 FILSPARI sales multiplied by four, not a forecast. None of these may happen, and actual results may differ materially. Richport has not independently verified them and will not update them. Read Travere's SEC filings, including the risk factors in its Form 10-K and Form 10-Q, for a full discussion.

References
- Focal segmental glomerulosclerosis — MedlinePlus, U.S. National Library of Medicine
- Travere Therapeutics Form 8-K: FDA approval of FILSPARI in FSGS — SEC EDGAR (April 13, 2026)
- Travere Therapeutics second quarter 2026 results (Form 8-K, Ex. 99.1) — SEC EDGAR (August 2026)
- FILSPARI (sparsentan) prescribing information — U.S. Food and Drug Administration (2026)
- Travere Therapeutics Form 10-Q for the quarter ended June 30, 2026 — SEC EDGAR (August 4, 2026)
- HARMONY: Phase 3 study of pegtibatinase in classical homocystinuria, NCT06247085 — ClinicalTrials.gov
- Travere Therapeutics corporate overview (May 2026) — Company source: Travere Therapeutics (May 2026)
- USRDS Annual Data Report, Vol. 2, Ch. 9: Healthcare expenditures for persons with ESRD — U.S. Renal Data System, NIDDK (2018)
- Travere Therapeutics Form 8-K: CEO succession — SEC EDGAR (September 21, 2026)
lobal Securities News